ArticleJournal of pharmacy & bioallied sciences2025
Clinical Evaluation of Cardiac Failure in Post-Myocardial Infarction Patients.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To assess the complications of myocardial infarction (MI) and evaluate the precautionary and preventive measures in patients developing cardiac failure post-MI. Materials and Methods: This 12-month prospective observational research at a tertiary care facility included 65 post-MI patients. A thorough clinical evaluation, Electrocardiogram (ECG), and two-dimensional echocardiogram (2D ECHO) were performed on patients. Study variables included functional cardiac anomalies, chamber enlargement, Regional wall motion abnormality (RWMA), New York heart association (NYHA) classification, and comorbidities. Results: In 59% of 2D ECHO patients, segmental dysfunction was the most frequent functional abnormality. The main chamber findings were left ventricular hypertrophy (32%) and left atrial enlargement (29%). Clinically, 78% had paroxysmal nocturnal dyspnea (PND)/orthopnea and 67% were NYHA Class III or IV. The most common comorbidities were hypertension (72%) and diabetes (60%). Conclusion: Segmental myocardial dysfunction, structural chamber anomalies, and particular ECG patterns substantially predict post-MI cardiac failure. This high-risk group needs early echocardiography, strong risk factor control, and timely heart failure treatment to decrease progression and enhance outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.